GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
COPD severity analysis according to current evaluation criteria – National survey Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015
Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Glycopyrronium significantly improves lung function, dyspnea and health status in COPD patients in all GOLD groups Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Heterogeneity inside group D COPD patients: About 827 cases Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016
Changes in lung function and comorbidity in patients with COPD over 4 to 10 years of follow-up Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement Year: 2013
Static and dynamic balance in patients with COPD: Comparison with healthy subjects and differences according to gender and disease severity Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in COPD Year: 2013
Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Comparison of comorbidities between two different subgroups in combined assessment of COPD Source: International Congress 2016 – Postural balance, respiratory muscles, and comorbidities in chronic respiratory disease Year: 2016
Statistical analysis of anthropometric differences between COPD stages 1 and 2 Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016
Relationship of baseline or annual change of clinical parameters on mortality in patients with COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013
Clinical characteristics and outcomes of elderly patients with COPD: TIOSPIR® post-hoc analysis Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016
Comparison of COPD patients with high and low symptoms from a real-world US survey Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases Year: 2015
Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016